熱門資訊> 正文
Ascendis Pharma GAAP每股收益为-1.91欧元，收入为3600万欧元;修订了24财年收入展望
2024-09-04 13:43
- Ascendis Pharma press release (ASND): Q2 GAAP EPS of -€1.91.
- Revenue of €36M (-24.0% Y/Y).
- SKYTROFA Q2 revenue of €26 million – 134% year-over-year volume growth offset by negative adjustment of €27 million, resetting market access for continued growth.
- As of June 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €259 million, compared to €399 million as of December 31, 2023.
- Revising full year 2024 SKYTROFA revenue outlook to €220 - €240 million.
- Expect total operating expenses (SG&A and R&D) to be approximately €600 million for 2024.
- Pending launch timing of YORVIPATH in the U.S., expect to be operating cash flow breakeven on a quarterly basis in 2024 or 2025.
More on Ascendis Pharma
- Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
- Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity
- Ascendis and Royalty Pharma enter into $150M royalty funding agreement
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
